I continue to follow CGPI and am encouraged by recent results of phase two studies and the intention to move to phase three. I believe another important study from the NCI should be out soon. I think the IVAX news underscores the marketability of low dose dox and the Fed court injunction remains intact. IVAX cannot get a ANDA through. Last info indicates the FDA case will not resolve til '05 if then. IVAX certainly re-enforces the risk of ownership. The question always is... is the percieved risk greater than the true risk?The company is cash flow positive, has good research (I am unaware of any other company that has anything resembling an ORAL well tolerated anti-angiogenesis drug moving to phase three) and has a great chance to hold on to the low dose dox patent (see the prior court record referenced in the original post)On the short term price gyrations. I do think 9 is a great entry point and I'll take 9.5 to start filling out. I was disappointed that order didn't fill today. CGPI has growing products and a fascinating research program. I just don't see alot of other small semi-undiscovered companies out there with already positive cash flow, profits, and potentially blockbuster research... I'm sure that's because of my own myopia... I would LOVE to have them pointed outI see loads of cash burning bio-techs w/ great potential. I repeatly tell my children "please don't let great potential deter you from success" I continue to think CGPI is a great shot and look to filling out in the 9-9.5 range. At a full position it will remain a small portion of my total investment pie.e
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ra